OpenAI 收购 Orchestra Bio，将其并入 Rosalind 开发药物研发智能体
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI 收购了帮助制药团队协调药物开发的初创公司 Orchestra Bio，并将其并入生命科学 AI 平台 Rosalind。双方计划构建连接科学发现、临床试验、决策与后续步骤的智能体；Orchestra 的智能体可跟踪试验、在生产批次失败等情况发生时标记受影响的时间线，并提供后续选项。交易金额未披露。
收购将 Orchestra Bio 的药物开发协调能力并入 Rosalind，文中列出的临床试验跟踪与时间线预警展示了这笔交易的应用方向。
OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools.
The combined effort aims to build AI agents that link scientific findings with clinical trials, decisions, and next steps to get new drugs to patients faster. Developing a drug in the US takes ten to 15 years on average. Beyond the scientific hurdles, siloed systems and the constant back-and-forth between internal teams and outside partners slow things down.
Orchestra's agents are designed to take work off teams' plates by tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next. That could free scientists to focus on decisions and the actual research. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. Financial terms of the deal weren't disclosed.
AI News Without the Hype – Curated by Humans
Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.
来源：The Decoder · the-decoder.com